Application of apatinib combined with radiotherapy in the treatment of prostate cancer with bone metastasis

Feng ZHAO,Wei TIAN,Ming ZENG,Jian-ling XIA,Hong-lin HU,Hao LIU,Yang-ke HE,Xue-qiang ZHU,Liang LIANG,Rui Ao,Ke XIE

DOI: https://doi.org/10.3969/j.issn.1672-6170.2017.04.004

2017-01-01

Abstract:Objective Objective To Investigate whether there was a synergistic anti-tumor effect of apatinib in combination of stereotactic radiotherapy (SBRT) in the treatment of prostate cancer patients with bony metastasis,and evaluate its efficacy and safety.Methods We selected 29 prostate cancer patients with bony metastasis and divided them into experimental group (n =19) and control group (n =10).The experimental group was given 250 mg apatinib daily combined with SBRT (6 Gy/fraction,5 fraction in total)while the control group was given 250 mg apatinib daily alone.The changes in serum prostate specifc antigen (PSA) and pain relief as well as adverse reaction were compared between the two groups.Results The pain relief in the experimental group was superior to the control group.Patients with PSA declines of ≥50％ in the experimental group were more than that in the control group.The duration of PSA decline was 2 ～ 6 months in the both groups.SBRT did not increase the rate of 3-degree adverse reaction.Conclusion Apatinib at dose of 250 mg daily in combination of RT synergized pain control.Further studies with large sample size are needed